Please login to the form below

Not currently logged in
Email:
Password:

EU clears Gilead's hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus
Gilead Sciences

Gilead Sciences has been granted approval by the European Commission (EC) for Sovaldi, getting a green light for the first all-oral treatment for chronic hepatitis C virus in the EU.

The European regulator approved Sovaldi (sofosbuvir) for use both in combination with pegylated interferon alpha and ribavirin in patients with hepatitis C genotypes 1, 4, 5 or 6, and as an interferon-free regimen alongside ribavirin alone in patients with hepatitis C genotypes 2 or 3 or those awaiting a liver transplant.

Gilead's drug - which is the first compound in the NS5B polymerase inhibitor class to be registered - was approved for the same indication in the US in December 2013, and analysts are already predicting that it could reach blockbuster sales levels of $1bn or more by the end of this year and $5bn or more at peak.

One reason for the anticipated rapid take-up of Sovaldi is that hepatitis C patients have been delaying treatment - a phenomenon known as 'warehousing' - in anticipation of the availability of more effective and tolerable new therapies.

Commenting on the EU approval of Gilead's drug, hepatologist Graham Foster of Queen Mary University in London, UK, said: "With high cure rates across a broad range of patients and a short duration of therapy, Sovaldi is a very welcome therapeutic advance."

Despite the fact that hepatitis C is curable, there is a pressing need for new and improved therapies because "many hepatitis C virus patients have not currently achieved a cure and often progress to end-stage liver disease or liver cancer," he added.

Gilead notes that approximately nine million people in Europe are infected with hepatitis C virus, which is a major cause of liver cancer and liver transplantation.

EU approval of Sovaldi is also a boost for Bristol-Myers Squibb (BMS), which moved a step closer to approval of a combination regimen of sofosbuvir and its NS5A inhibitor daclatasvir earlier this year after the EMA's Committee for Medicinal Products for Human use said the two drugs could be used on a compassionate basis in hepatitis C patients at high risk of liver failure or death.

BMS is hoping to position daclatasvir alongside sofosbuvir as the basis of an all-oral, interferon-free regimen of choice for hepatitis C.

Meanwhile, a host of other drugmakers are also vying for a share of the interferon-free market for hepatitis C, including Johnson & Johnson and Medivir, whose protease inhibitor Olysio (simeprevir) was cleared in the US in November 2013. The likes of AbbVie, Boehringer Ingelheim and Merck & Co all also have candidates in development.

Article by
Phil Taylor

20th January 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics